新型超声评分系统引导认知融合靶向活检的前瞻性研究
该前瞻性研究纳入452例活检初治、PSA≤20 ng/ml的患者共531个PI-RADS v2.1≥3病灶,开发并验证超声评分系统(USS)辅助认知融合靶向活检。USS 0~3分总体癌检出率分别为0%、66%、83%、100%;USS+PI-RADS的AUC 0.85优于单独PI-RADS 0.77(P<0.001),敏感度80.7% vs 72.5%。
要点
- USS 0分病灶各PI-RADS分层csPCa阳性率均为零,可提示低风险。
- USS 2分和3分病灶分别靶向第3针和第2针后检出率无显著增加。
- USS+PI-RADS联合诊断AUC 0.85,优于单独PI-RADS 0.77。
核心结论
- 在认知融合靶向活检中,USS对癌症风险再分层表现良好,USS评分越高癌症可能性越大、诊断准确度越高。
研究设计与样本
- 前瞻性研究,纳入452例活检初治、PSA≤20 ng/ml患者共531个PI-RADS v2.1≥3病灶,所有MRI感兴趣区在经直肠超声上对应评分USS 0~3分,以活检病理为参考标准。
关键影像表现/征象
- MRI感兴趣区在经直肠超声上对应病灶或区域评为USS 0、1、2、3分。
- USS 0~3分总体癌检出率分别为0%(0/67)、66%(111/166)、83%(176/210)、100%(59/59)。
诊断标准与关键数值
- USS 2分病灶靶向第3针检出率79%(P=0.774),后续活检针检出率无显著增加。
- USS 3分病灶靶向第2针检出率93%(P=0.125),后续活检针检出率无显著增加。
- USS+PI-RADS的AUC 0.85(95%CI 0.82-0.89)优于单独PI-RADS 0.77(95%CI 0.73-0.81),P<0.001。
- USS+PI-RADS敏感度80.7%(95%CI 75.6-84.9),单独PI-RADS敏感度72.5%(95%CI 67.6-77.0)。
临床应用与阅片要点
- USS 0分病灶在各PI-RADS分层中csPCa阳性率均为零,可辅助识别低风险病灶。
- USS 1、2、3分在各PI-RADS分层内均提高csPCa阳性率,可用于风险再分层。
- USS 2分病灶靶向第3针、USS 3分病灶靶向第2针后检出率无显著增加,提示活检针数可参考USS评分调整。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To develop and validate a novel ultrasound scoring system (USS) for assisting cognitive fusion-targeted biopsy (cTB).
METHODS: We prospectively collected a study cohort consisting of 452 patients with biopsy-naïve, PSA ≤ 20 ng/ml and their 531 Prostate Imaging Reporting and Data System (PI-RADS) v2.1 ≥ 3 lesions. All MRI regions of interest were scored as USS 0, 1, 2, and 3 for the corresponding lesion or region on TRUS. The cumulative cancer detection rate of the biopsy cores was assessed according to USS. Subgroup analysis was conducted to assess the csPCa detection rate following the re-stratification of PI-RADS using USS. Receiver operating characteristics (ROC) analysis was performed for USS, PI-RADS and USS + PI-RADS. The area under the curve (AUC), sensitivity, and specificity were calculated at the cut-off selected by the Youden index.
RESULTS: The overall cancer detection rates for USS scores of 0 to 3 were 0% (0/67), 66% (111/166), 83% (176/210), and 100% (59/59), respectively. For USS 2 and USS 3 lesions, the detection rates in targeting the 3rd core (79%, P = 0.774) and 2nd core (93%, P = 0.125) did not significantly increase with subsequent biopsy cores. In the subgroup analysis, the csPCa positive rate for USS 0 was zero across all PI-RADS categories. In contrast, USS 1, 2, and 3 enhanced the csPCa positive rate within each PI-RADS strata. In ROC analysis, the AUC (95% CI) for the combined USS + PI-RADS 0.85 (0.82-0.89) outperformed PI-RADS 0.77 (0.73-0.81) alone (P < 0.001). USS + PI-RADS sensitivity (95% CI) was 80.7% (75.6-84.9) compared to PI-RADS 72.5% (67.6-77.0).
CONCLUSION: In cTB, USS has good performance in cancer risk re-stratification, with higher USS scores correlating with an increased likelihood of cancer and improved diagnostic accuracy.
CLINICAL TRIAL REGISTRATION: No. 2023-272-002, July 14, 2023.
引用
- Qin F, Wu J, Ma J, et al. Novel ultrasound scoring system to guide cognitive fusion-targeted biopsy: a prospective study. Abdom Radiol (NY). 2025. PMID: 40220167. doi:10.1007/s00261-025-04903-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。